UY38068A - Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico - Google Patents

Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Info

Publication number
UY38068A
UY38068A UY38068A UY38068A UY38068A UY 38068 A UY38068 A UY 38068A UY 38068 A UY38068 A UY 38068A UY 38068 A UY38068 A UY 38068A UY 38068 A UY38068 A UY 38068A
Authority
UY
Uruguay
Prior art keywords
relaxin
lipided
modified
therapeutic use
chain peptides
Prior art date
Application number
UY38068A
Other languages
English (en)
Inventor
Illiano Stéphane
Sergio Mallart
Minoletti-Hochepied Claire
Frank Marguet
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Denis Brasseur
Olivier Duclos
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY38068A publication Critical patent/UY38068A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un péptido de Relaxina monocatenario biológicamente activo que tiene la siguiente fórmula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; o una sal o solvato de este. También trata sobre una composición farmacéutica que comprende al menos un péptido de la invención, y el péptido o la composición farmacéutica para su uso como un medicamento.
UY38068A 2018-01-31 2019-01-31 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico UY38068A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305093 2018-01-31

Publications (1)

Publication Number Publication Date
UY38068A true UY38068A (es) 2019-08-30

Family

ID=61223861

Family Applications (1)

Application Number Title Priority Date Filing Date
UY38068A UY38068A (es) 2018-01-31 2019-01-31 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Country Status (5)

Country Link
US (1) US10988523B2 (es)
AR (1) AR114324A1 (es)
TW (1) TW201940504A (es)
UY (1) UY38068A (es)
WO (1) WO2019149781A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
WO2019149781A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
CA3089657A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160152679A1 (en) * 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
CA2945838C (en) 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
WO2019149781A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
CA3089657A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途

Also Published As

Publication number Publication date
WO2019149781A1 (en) 2019-08-08
US10988523B2 (en) 2021-04-27
US20190233493A1 (en) 2019-08-01
AR114324A1 (es) 2020-08-19
TW201940504A (zh) 2019-10-16

Similar Documents

Publication Publication Date Title
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
AR099976A1 (es) Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
AR108631A1 (es) Formulación de neurotoxinas
AR105712A1 (es) Composiciones de insulina de rápida acción
PE20200606A1 (es) Composiciones solidas para administracion oral
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico